Biohaven Ltd. – Filings and Transcripts

NYSE: BHVN
Share price (10/7/26): $11.88
Market cap (10/7/26): $1.794 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Automatic shelf registration

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Gentile Kimberly

Woodline Partners LP

Volles Warren Karl

Janus Henderson Group plc

News Filter

Biohaven and SK Biopharmaceuticals Enter Into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Reports Recent Business Developments and Second Quarter 2026 Financial Results

Change in Directors, Officers or Compensation, Financial Statements or Exhibits

Announces Scientific Leadership Transitions

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Confidential treatment order

Notice of effectiveness

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC